Independent Research set a €53.00 ($61.63) price target on Fresenius SE & Co KGaA (FRA:FRE) in a report released on Friday morning. The brokerage currently has a neutral rating on the stock.

Other analysts have also issued research reports about the stock. Kepler Capital Markets set a €65.00 ($75.58) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Friday. UBS Group set a €51.50 ($59.88) price target on shares of Fresenius SE & Co KGaA and gave the company a sell rating in a report on Friday. Goldman Sachs Group set a €61.00 ($70.93) price target on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Friday. Commerzbank set a €78.00 ($90.70) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Friday. Finally, HSBC set a €59.00 ($68.60) price target on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Tuesday. One analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the stock. Fresenius SE & Co KGaA currently has an average rating of Buy and an average target price of €68.69 ($79.88).

Shares of FRA FRE traded down €8.39 ($9.76) during mid-day trading on Friday, hitting €38.99 ($45.34). 12,548,201 shares of the stock were exchanged. Fresenius SE & Co KGaA has a twelve month low of €60.16 ($69.95) and a twelve month high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: Asset Allocation, Balancing Your Investments

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.